We found that regorafenib administration restricts ERK1/2 and STAT3 activation in CRC cells and xenografted tumors with diverse gene subtypes, including TAS102-induced ERK1/2 or STAT3 activation (Figures 4F, 4G and 5B, 5D). The gene discussed is MAPK3; the disease is colorectal carcinoma.